Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants

NCT05810038 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05810038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05810038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Chinese Participants
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
May 15, 2023
Completion date
December 10, 2025
Enrollment
787 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

migraine